Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients

Neurological Research

Volumn 35, Issue 9, 2013, Pages 922-929

  Long, Youming ^a,b   Gao, Cong ^b   Qiu, Wei ^a   Hu, Xueqiang ^a   Peng, Fuhua ^a   Lu, Zhengqi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antibody; Aquaporin 4; Microvessel; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4; ENDOTHELIAL CELL ANTIBODY; IMMUNOGLOBULIN G; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN; CHILD; CONTROLLED STUDY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PILOT STUDY; SEROLOGY; STOMACH; UMBILICAL VEIN ENDOTHELIAL CELL;

ADOLESCENT; ADULT; AQUAPORIN 4; AUTOANTIBODIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN G; MALE; MICROVESSELS; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; YOUNG ADULT;

EID: 84885587517     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132813Y.0000000229     Document Type: Article

References (40)

1. de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler. 2003;9(5):521-5.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-14.
3. Cheng Q, Miao L, Zhang J, Guan YT, Liu ZG, Wang X, et al. Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Mult Scler. 2008;14(5):671-8.
4. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176-80.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12.
6. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-7.
7. Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52.
8. De Vidi I, Boursier G, Delouche N, Portalès P, Cadars E, Bouthier M, et al. Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol. 2011;138(3):239-46.
9. Long Y, Qiu W, Lu Z, Bao J, Wu A, Wang Y, et al. Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica. Neuroimmunomodulation. 2012;19(2):96-102.
10. Long Y, Hu X, Peng F, Wang Y, Yang Y, Qiu W, et al. Neuromyelitis optica immunoglobulin G in Chinese patients detected by immunofluorescence assay on a monkey brain substrate. Neuroimmunomodulation. 2012;19(1):20-4.
11. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-9.
12. Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010;298(1-2):158-62.
13. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-200.
14. Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol. 2006;63(10):1398-400.
15. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2): 292-302.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52.
17. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390-6.
18. Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int. 2012;2012:735486.
19. Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13(2):256-9.
20. Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18(1):108-12.
21. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239-45.
22. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder. Mult Scler. 2012;18(10):1480-3.
23. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012;18(1):113-5.
24. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
25. Jarius S, Paul F, Franciotta D, de Seze J, Münch C, Salvetti M, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler. 2012;18(8):1135-43.
26. Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 autoantibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev. 2009;9(2):132-5.
27. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383-92.
28. Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, et al. Sera from neuromyelitis optica patients disrupt the bloodbrain barrier. J Neurol Neurosurg Psychiatry. 2012;83(3):288-97.
29. Kinoshita M, Nakatsuji Y. Where do AQP4 antibodies fit in the pathogenesis of NMO. Mult Scler Int. 2012;2012:862169.
30. Ratelade J, Bennett JL, Verkman AS. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem. 2011;286(52):45156-64.
31. Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations. Semin Ophthalmol. 2008;23(3):191-200.
32. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450-61.
33. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78-83.
34. Alves-Leon SV, Pimentel ML, Sant'Anna G, Malfetano FR, Estrada CD, Quirico-Santos T. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq Neuropsiquiatr. 2008;66(3B):678-84.
35. Jarius S, Neumayer B, Wandinger KP, Hartmann M, Wildemann B. Anti-endothelial serum antibodies in a patient with Susac's syndrome. J Neurol Sci. 2009;285(1-2):259-61.
36. Magro CM, Poe JC, Lubow M, Susac JO. Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol. 2011;136(6):903-12.
37. Belizna C, Duijvestijn A, Hamidou M, Tervaert JW. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis. 2006;65(12):1545-50.
38. Tintore M, Fernandez AL, Rovira A, Martinez X, Direskeneli H, Khamashta M, et al. Antibodies against endothelial cells in patients with multiple sclerosis. Acta Neurol Scand. 1996;93(6):416-20.
39. Kotaska K, Petrak B, Kukacka J, Kraus J, Prusa R. Anti-vimentin antibodies and neuron-specific enolase in children with neurofibromatosis type-1. Neuro Endocrinol Lett. 2007;28(6):761-4.
40. BellDA, Thiem PA, Vaughan JH, Leddy JP. Studies with human leukocyte lysosomes. Evidence for antilysosome antibodies in lupus erythematosus and for the presence of lysosomal antigen in inflammatory diseases. J Clin Invest. 1975;55(2):256-68.